ITMI20070721A1 - DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. - Google Patents
DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. Download PDFInfo
- Publication number
- ITMI20070721A1 ITMI20070721A1 ITMI20070721A ITMI20070721A1 IT MI20070721 A1 ITMI20070721 A1 IT MI20070721A1 IT MI20070721 A ITMI20070721 A IT MI20070721A IT MI20070721 A1 ITMI20070721 A1 IT MI20070721A1
- Authority
- IT
- Italy
- Prior art keywords
- substance
- activity
- composition according
- dermatitis
- restructuring
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 34
- 201000004624 Dermatitis Diseases 0.000 title claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 title claims description 13
- 201000008937 atopic dermatitis Diseases 0.000 title claims description 13
- 206010048222 Xerosis Diseases 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 title claims description 9
- 230000001575 pathological effect Effects 0.000 title claims description 8
- 239000000126 substance Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 28
- 230000001681 protective effect Effects 0.000 claims description 11
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 239000003974 emollient agent Substances 0.000 claims description 9
- 230000035876 healing Effects 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 9
- 230000003020 moisturizing effect Effects 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 7
- 235000017336 Capparis spinosa Nutrition 0.000 claims description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical group NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 235000013311 vegetables Nutrition 0.000 claims description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 244000144725 Amygdalus communis Species 0.000 claims description 4
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 4
- 241000722721 Capparis Species 0.000 claims description 4
- 240000001439 Opuntia Species 0.000 claims description 4
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 4
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 4
- 235000020224 almond Nutrition 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 229940057910 shea butter Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims description 3
- 229940033329 phytosphingosine Drugs 0.000 claims description 3
- MFCMBWRHOUCXEZ-CAHLUQPWSA-N 3-aminopropyl [(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] hydrogen phosphate Chemical compound NCCCOP(O)(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O MFCMBWRHOUCXEZ-CAHLUQPWSA-N 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 244000140995 Capparis spinosa Species 0.000 claims description 2
- 240000003537 Ficus benghalensis Species 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 4
- 229960004544 cortisone Drugs 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 229960003885 sodium benzoate Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BBAFBDLICMHBNU-MFZOPHKMSA-N N-(2-hydroxyoctadecanoyl)-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCC(O)C(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC BBAFBDLICMHBNU-MFZOPHKMSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- MIUIRGGKIICMBP-NFOZDHADSA-N [27-oxo-27-[[(2s,3s,4r)-1,3,4-trihydroxyoctadecan-2-yl]amino]heptacosyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC MIUIRGGKIICMBP-NFOZDHADSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940048864 ceramide 1 Drugs 0.000 description 1
- 229940044176 ceramide 3 Drugs 0.000 description 1
- 229940095137 ceramide 6 ii Drugs 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
DESCRIZIONE DESCRIPTION
La presente invenzione è relativa ad una composizione dermocosmetica, in particolare per il trattamento di dermatiti e altre patologie della pelle e specificamente della dermatite atopica, anche associata a xerosi patologica. The present invention relates to a dermocosmetic composition, in particular for the treatment of dermatitis and other pathologies of the skin and specifically of atopic dermatitis, also associated with pathological xerosis.
La dermatite atopica (o eczema costituzionale) è una patologia caratteristica del bambino che però si riscontra anche in soggetti adulti; è una dermatite fortemente pruriginosa caratterizzata da una iperreattività cutanea a stimoli irritativi o immunologici. Sul piano biologico la cute nella dermatite atopica è caratterizzata, tra l'altro, da una diminuzione delle funzioni di barriera cutanee, dovuta ad una carenza di lipidi cutanei. Questo difetto comporta un aumento della perdita di acqua attraverso la cute. Infatti la pelle del paziente atopico è tipicamente "secca" e facilmente irritabile (xerosi patologica). Il danno della barriera cutanea favorisce la penetrazione di molecole irritanti e/o sensibilizzanti che inducono una risposta infiammatoria. La cute del soggetto atopico tende a reagire in modo eccessivo a stimoli normalmente ben tollerati quali il contatto con l'acqua, i detergenti, le fibre tessili, la sudorazione, le differenze di temperatura tra l'ambiente domestico e l'esterno, condizioni di stress. Atopic dermatitis (or constitutional eczema) is a characteristic pathology of the child which, however, is also found in adults; it is a strongly itchy dermatitis characterized by skin hyperreactivity to irritative or immunological stimuli. On a biological level, the skin in atopic dermatitis is characterized, among other things, by a decrease in skin barrier functions, due to a lack of skin lipids. This defect leads to an increase in the loss of water through the skin. In fact, the skin of the atopic patient is typically "dry" and easily irritated (pathological xerosis). Damage to the skin barrier favors the penetration of irritating and / or sensitizing molecules that induce an inflammatory response. The skin of the atopic subject tends to overreact to normally well tolerated stimuli such as contact with water, detergents, textile fibers, sweating, temperature differences between the home and the outside, conditions of stress.
La manifestazione clinica caratteristica della dermatite atopica è l'eczema; il prurito è un sintomo costante, per cui alle lesioni proprie della dermatite si possono associare lesioni da grattamento. The characteristic clinical manifestation of atopic dermatitis is eczema; itching is a constant symptom, so scratching lesions can be associated with the lesions of dermatitis.
A livello farmacologico, il trattamento della fase infiammatoria della dermatite atopica è normalmente condotto con cortisone topico; il cortisone attenua la componente infiammatoria della dermatite, riduce il prurito e così facendo interrompe il circolo vizioso che dal prurito porta al grattamento, da questo a nuova irritazione cutanea e quindi a nuovo prurito. Tuttavia il cortisone deve essere utilizzato con cautela e senza dimenticare i suoi effetti collaterali, considerata la cronicità della dermatite e quindi la durata necessariamente lunga della terapia. At the pharmacological level, the treatment of the inflammatory phase of atopic dermatitis is normally carried out with topical cortisone; cortisone attenuates the inflammatory component of dermatitis, reduces itching and in doing so interrupts the vicious circle that from itching leads to scratching, from this to new skin irritation and then to new itching. However, cortisone must be used with caution and without forgetting its side effects, given the chronicity of the dermatitis and therefore the necessarily long duration of therapy.
Al di fuori del settore propriamente farmaceutico, la dermatite atopica è trattata essenzialmente con sostanze emollienti che contrastano la xerosi e rafforzano la barriera cutanea rendendo la pelle meno irritabile (e riducendo quindi l'utilizzo del farmaco cortisonico). Outside the strictly pharmaceutical sector, atopic dermatitis is essentially treated with emollient substances that counteract xerosis and strengthen the skin barrier, making the skin less irritable (and therefore reducing the use of the cortisone drug).
I prodotti attualmente disponibili non sono però pienamente soddisfacenti, per cui sorge l'esigenza di disporre di una composizione dermocosmetica non farmaceutica {vale a dire una composizione utilizzabile in campo cosmetico e non soggetta alla legislazione che regola i prodotti farmaceutici) che sia di impiego sicuro ed efficace nel trattamento della dermatite atopica e di altre patologie della pelle. However, the products currently available are not fully satisfactory, so the need arises to have a non-pharmaceutical dermocosmetic composition (i.e. a composition usable in the cosmetic field and not subject to the legislation that regulates pharmaceutical products) that is of safe use and effective in the treatment of atopic dermatitis and other skin diseases.
È dunque uno scopo della presente invenzione quello di fornire una composizione dermocosmetica ad effetto lenitivo e ristrutturante che possa essere efficacemente impiegata per il trattamento della dermatite atopica, anche associata a xerosi patologica, e più in generale di dermatiti e altre patologie della pelle . It is therefore an object of the present invention to provide a dermocosmetic composition with a soothing and restructuring effect that can be effectively used for the treatment of atopic dermatitis, also associated with pathological xerosis, and more generally of dermatitis and other skin diseases.
In accordo con tali scopi, la presente invenzione è relativa ad una composizione dermocosmetica, in particolare per il trattamento di dermatiti e altre patologie della pelle e specificamente della dermatite atopica, anche associata a xerosi patologica, caratterizzata dal fatto di comprendere una associazione di una sostanza ad attività ristrutturante, una sostanza ad attività antinfiammatoria e protettiva, una sostanza ad attività cheratoplastica, e una sostanza ad attività immunostimolante, idratante e cicatrizzante. In accordance with these purposes, the present invention relates to a dermocosmetic composition, in particular for the treatment of dermatitis and other skin pathologies and specifically of atopic dermatitis, also associated with pathological xerosis, characterized in that it comprises an association of a substance with restructuring activity, a substance with anti-inflammatory and protective activity, a substance with keratoplastic activity, and a substance with immunostimulating, moisturizing and healing activity.
La sostanza ad attività ristrutturante è preferibilmente un complesso lipidico ad attività ristrutturante, specificamente un complesso ceramidico che comprende una o più ceramidi e opzionalmente fitosfingosina. Ad esempio, il complesso ceramidico comprende ceramide 1, ceramide 3, ceramide 6 II e fitosfingosina. La sostanza ad attività ristrutturante è presente per esempio a concentrazioni comprese tra circa 0,5% e circa 5%, e preferibilmente tra circa 1% e circa 2,5%. The substance with restructuring activity is preferably a lipid complex with restructuring activity, specifically a ceramide complex which comprises one or more ceramides and optionally phytosphingosine. For example, the ceramide complex includes ceramide 1, ceramide 3, ceramide 6 II and phytosphingosine. The substance with restructuring activity is present for example at concentrations comprised between about 0.5% and about 5%, and preferably between about 1% and about 2.5%.
La sostanza ad attività antinfiammatoria e protettiva è preferibilmente una sostanza con elevato contenuto di flavonoidi (in particolare chemferolo e quercitina) , per esempio un estratto di cappero ( Capparis spinosa.) , ed è presente per esempio a concentrazioni comprese tra circa 0,1% e circa 1%, e preferibilmente tra circa 0,4% e circa 0,8%. The substance with anti-inflammatory and protective activity is preferably a substance with a high content of flavonoids (in particular chemferol and quercetin), for example a caper extract (Capparis spinosa.), And is present for example at concentrations between about 0.1% and about 1%, and preferably between about 0.4% and about 0.8%.
La sostanza ad attività cheratoplastica ed emolliente è preferibilmente allontoina ed è per esempio presente a concentrazioni comprese tra circa 0,1% e circa 1%, e preferibilmente tra circa 0,4% e circa 0,8%. The substance with keratoplastic and emollient activity is preferably allontoin and is for example present at concentrations comprised between about 0.1% and about 1%, and preferably between about 0.4% and about 0.8%.
La sostanza ad attività immunostimolante , idratante e cicatrizzante è preferibilmente una sostanza contenente polisaccaridi, per esempio un estratto di fico d'india (Opunzia Ficus indica) , presente per esempio a concentrazioni comprese tra circa 0,1 e circa 2%, e preferibilmente tra circa 0,4 e circa 1,0%. The substance with immunostimulating, moisturizing and healing activity is preferably a substance containing polysaccharides, for example a prickly pear extract (Opunzia Ficus indica), present for example at concentrations between about 0.1 and about 2%, and preferably between about 0.4 and about 1.0%.
L'associazione tra i vari componenti in accordo all'invenzione consegue effetti che vanno al di là della semplice somma di effetti che ci si aspetterebbe dai singoli componenti, in quanto la composizione del trovato, oltre a non avere alcuna controindicazione o effetto collaterale, non solo lenisce e attenua i sintomi della dermatite, ma addirittura porta ad una regressione della patologia che normalmente non è possibile ottenere se non con trattamento farmacologico . The association between the various components according to the invention achieves effects that go beyond the simple sum of effects that one would expect from the individual components, since the composition of the invention, in addition to having no contraindication or side effect, does not it only soothes and attenuates the symptoms of dermatitis, but even leads to a regression of the pathology that normally cannot be obtained except with pharmacological treatment.
L'invenzione è dunque relativa, in termini generali, all'uso di una associazione di una sostanza ad attività ristrutturante, specificamente un complesso lipidico ad attività ristrutturante, una sostanza ad attività antinfiammatoria e protettiva, una sostanza ad attività cheratoplastica, e una sostanza ad attività immunostimolante , idratante e cicatrizzante per la fabbricazione di una composizione dermocosmetica per il trattamento di dermatiti e altre patologie della pelle e specificamente della dermatite atopica, anche associata a xerosi patologica. The invention therefore relates, in general terms, to the use of an association of a substance with restructuring activity, specifically a lipid complex with restructuring activity, a substance with anti-inflammatory and protective activity, a substance with keratoplastic activity, and a substance with immunostimulating, moisturizing and healing activity for the manufacture of a dermocosmetic composition for the treatment of dermatitis and other skin diseases and specifically of atopic dermatitis, also associated with pathological xerosis.
Secondo una preferita forma di attuazione, la composizione è in forma di emulsione di tipo olio-inacqua; preferibilmente, l'emulsione è su base vegetale e contiene un emulsionante vegetale lipoproteico. According to a preferred embodiment, the composition is in the form of an oil-in-water emulsion; preferably, the emulsion is vegetable-based and contains a lipoprotein vegetable emulsifier.
Opzionalmente, la composizione del trovato comprende inoltre lipidi naturali selezionati nel gruppo costituito da: Optionally, the composition of the invention further comprises natural lipids selected from the group consisting of:
- frazioni insaponificabili di olio di oliva; - unsaponifiable fractions of olive oil;
- cera di mandorle (parte cerosa di olio di mandorle); - burro di karitè; - almond wax (waxy part of almond oil); - shea butter;
vitageno F (miscela di acidi grassi insaturi essenziali vegetali: acido linoleico, acido linolenico, acido arachidonico); vitageno F (mixture of essential vegetable unsaturated fatty acids: linoleic acid, linolenic acid, arachidonic acid);
- acido glicirretico e/o suoi derivati, in particolare derivati stearici come stearil-glicirretinato. - glycyrrhetic acid and / or its derivatives, in particular stearic derivatives such as stearyl-glycyrretinate.
Secondo un aspetto importante dell'invenzione, la composizione del trovato comprende poi un sistema tampone fisiologico (ad esempio sistema tampone fosfato o citrato o bicarbonato) per mantenere il pH della composizione a valori prestabiliti e specificamente compresi tra circa 4,5 e circa 6,5 e preferibilmente tra circa 5 e circa 6 (tampone fosfato). According to an important aspect of the invention, the composition of the invention further comprises a physiological buffer system (for example phosphate or citrate or bicarbonate buffer system) for maintaining the pH of the composition at predetermined values and specifically between about 4.5 and about 6, 5 and preferably between about 5 and about 6 (phosphate buffer).
L'invenzione viene ulteriormente descritta nei seguenti esempi di attuazione non limitativi. The invention is further described in the following non-limiting embodiments.
Sono state preparate diverse emulsioni olio-inacqua su base vegetale contenenti: Several plant-based oil-in-water emulsions have been prepared containing:
come sostanze di base: as basic substances:
emulsionante vegetale lipoproteico lipoprotein vegetable emulsifier
lipidi naturali natural lipids
e come sostanze funzionali: and as functional substances:
Complesso ceramidico 0,5÷5% (attività ristrutturante e reintegrante della barriera cutanea) 0.5 ÷ 5% ceramide complex (restructuring and reintegrating activity of the skin barrier)
Allantoina 0,1÷1,0% (attività cheratoplastica ed emolliente) Insaponificabile di olio d'oliva 5% Allantoin 0.1 ÷ 1.0% (keratoplastic and emollient activity) Olive oil unsaponifiable 5%
(azione emolliente e protettiva) (emollient and protective action)
Cera di mandorle 0,5% Almond wax 0.5%
(azione emolliente, idrorepellente e protettiva) Burro di karitè 3,5% (emollient, water-repellent and protective action) Shea butter 3.5%
(azione lenitiva e nutritiva) (soothing and nourishing action)
Vitageno F 1,5% Vitageno F 1,5%
(attività reintegrante della barriera cutanea) Stearil-glicerretinato 0,5% (replenishing activity of the skin barrier) Stearyl-glycerretinate 0.5%
(attività lenitiva) (soothing activity)
Estratto di cappero 0,1÷1% (attività antinfiammatoria e protettiva) Estratto di fico d'india 0,1÷2% (attività immunostimolante , idratante e cicatrizzante) Caper extract 0.1 ÷ 1% (anti-inflammatory and protective activity) Prickly pear extract 0.1 ÷ 2% (immunostimulating, moisturizing and healing activity)
Sistema preservante Preservative system
(fenossietanolo, potassio sorbato, sodio benzoato) Sistema tampone (fosfato, pH 5,5) (phenoxyethanol, potassium sorbate, sodium benzoate) Buffer system (phosphate, pH 5.5)
In particolare, è stata preparata specificamente, in accordo ad una preferita forma di attuazione dell'invenzione, la seguente composizione: In particular, the following composition has been specifically prepared, according to a preferred embodiment of the invention:
Complesso ceramidico 2% Allantoina 0,5% Insaponificabile di olio d'oliva 5% Ceramide complex 2% Allantoin 0.5% Olive oil unsaponifiables 5%
Cera di mandorle 0 , 5% Almond wax 0, 5%
Burro di karitè 3 , 5% Vitageno F 1 , 5% Shea butter 3.5% Vitagen F 1.5%
Stearil-glicerretinato 0 , 5% Estratto di cappero 0 , 5% Stearyl glycerretinate 0, 5% Caper extract 0, 5%
Estratto di fico d'india 0 , 5% Prickly pear extract 0.5%
Sistema preservante Preservative system
(fenossietanolo, potassio sorbato, sodio benzoato) Sistema tampone (fosfato, pH 5,5) (phenoxyethanol, potassium sorbate, sodium benzoate) Buffer system (phosphate, pH 5.5)
Resta comunque inteso che alle composizioni qui descritte a puro titolo esemplificativo possono essere apportate ulteriori modifiche e varianti che non escono dall'ambito delle annesse rivendicazioni. However, it is understood that further modifications and variations may be made to the compositions described here purely by way of example, which do not depart from the scope of the appended claims.
Claims (18)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20070721 ITMI20070721A1 (en) | 2007-04-06 | 2007-04-06 | DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20070721 ITMI20070721A1 (en) | 2007-04-06 | 2007-04-06 | DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20070721A1 true ITMI20070721A1 (en) | 2008-10-07 |
Family
ID=40327461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITMI20070721 ITMI20070721A1 (en) | 2007-04-06 | 2007-04-06 | DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20070721A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMO20120036A1 (en) * | 2012-02-15 | 2013-08-16 | Drex Pharma S R L | ADJUSTING COMPOSITION FOR TOPICAL USE |
-
2007
- 2007-04-06 IT ITMI20070721 patent/ITMI20070721A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMO20120036A1 (en) * | 2012-02-15 | 2013-08-16 | Drex Pharma S R L | ADJUSTING COMPOSITION FOR TOPICAL USE |
| EP2628487A1 (en) * | 2012-02-15 | 2013-08-21 | Drex Pharma S.R.L. | Adjuvant composition for topical use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alam et al. | In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis | |
| CN103520051B (en) | Hair and body shampoo | |
| Kanti et al. | Influence of sunflower seed oil on the skin barrier function of preterm infants: a randomized controlled trial | |
| CN106619337A (en) | Crowfoot crack resistant cream for infants and a preparing method thereof | |
| BR112021026374A2 (en) | cbd composition | |
| ES2501268T3 (en) | Keratin glyceride dryness treatment | |
| CN116270324A (en) | Bionic fetal fat nursing composition for moisturizing skin | |
| Katibi et al. | Moisturizer therapy in prevention of atopic dermatitis and food allergy: To use or disuse? | |
| RU2403047C2 (en) | Composition for reduction of serum protein exudation | |
| ES2394316T3 (en) | Pharmaceutical compositions of Carapa Guianensis. | |
| WO2013190542A2 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
| KR102558185B1 (en) | Cosmetic composition containing pseudo-ceramide originated from botanical oil | |
| ITMI20070721A1 (en) | DERMOCOSMETIC COMPOSITION, IN PARTICULAR FOR THE TREATMENT OF DERMATITIS AND OTHER PATHOLOGIES OF THE SKIN AND SPECIFICALLY OF ATOPIC DERMATITIS, ALSO ASSOCIATED WITH PATHOLOGICAL XEROSIS. | |
| US10307361B2 (en) | Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same | |
| Shrikhande | Formulation and evaluation of polyherbal topical anti-inflammatory emulgel | |
| IT201800002843A1 (en) | COMPOSITION FOR USE IN THE TREATMENT OF SEBORROIC DERMATITIS | |
| Imran et al. | Intranasal delivery of a silymarin loaded microemulsion for the effective treatment of parkinson’s disease in rats: formulation, optimization, characterization, and in vivo evaluation. Pharmaceutics 2023; 15: 618 | |
| US9610296B2 (en) | Inducing lactation in nursing females | |
| US20210011004A1 (en) | Method for changing condition of eyelid of hairless animal | |
| EP1520577A1 (en) | Cosmetic or dermatological composition comprising oil of evening primrose | |
| KR20140081967A (en) | A composition for improving atopic dermatitis containing green hempseed oil | |
| KR102289346B1 (en) | Preparation method of infused oil for skin soothing and atopy improvement | |
| DE102010030443A1 (en) | Cosmetic composition, useful e.g. for the prophylaxis and treatment of dry sensitive skin or eczematous and psoriatic skin, comprises cobalamin and an extract of plant of the family Berberidaceae, preferably from the genus Mahonia | |
| KR101945351B1 (en) | Cosmetic composition of intercellular lipid and it's liposome composition for anti-itching caused by skin drynesss | |
| Hyun et al. | Effects of topical moisturizers on the skin of healthy full-term infants and toddlers |